Méry Laure, Girot Robert, Aractingi Sélim
Service de Dermatologie, Hôpital Tenon, Paris, France.
Dermatology. 2004;208(2):135-7. doi: 10.1159/000076487.
Leg ulcers are a frequently neglected, severe complication of sickle cell disease (SCD), responsible for significant altering quality of life. The management of leg ulcers remains disappointing. Local application of recombinant human granulocyte-macrophage colony-stimulating factor has been shown to be effective in several types of chronic wound healing.
We report 5 homozygous sickle cell patients with 14 leg ulcers lasting from 1 month to 6 years, treated with topical dripping of molgramostim solution.
Healing was obtained for 9/14 ulcers, with no local or systemic adverse reactions.
Molgramostim solution appears to be an adequate therapy for SCD leg ulcers but a more conclusive evaluation will depend on larger series of patients and other types of formulations for topical applications could be even more effective in the future.
腿部溃疡是镰状细胞病（SCD）一种常被忽视的严重并发症，会显著影响生活质量。腿部溃疡的治疗效果仍然不尽人意。局部应用重组人粒细胞巨噬细胞集落刺激因子已被证明对几种慢性伤口愈合有效。
我们报告了5例纯合子镰状细胞病患者，他们有14处腿部溃疡，病程从1个月到6年不等，采用莫拉司亭溶液局部滴注治疗。
14处溃疡中有9处愈合，未出现局部或全身不良反应。
莫拉司亭溶液似乎是治疗SCD腿部溃疡的一种合适疗法，但更具结论性的评估将取决于更多的患者系列研究，并且未来其他类型的局部应用制剂可能会更有效。
